PF-Atlas › Clinical Trials › NCT06159725

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

CMTX-101 · Phase 1

Registry ID

NCT06159725

Phase

Phase 1

Status

Completed

Drug / intervention

CMTX-101

Sponsor

Clarametyx Biosciences, Inc.

Start

2024-06-24

Enrollment

Locations

About this trial

CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)

View NCT06159725 on ClinicalTrials.gov →

Explore related

All CMTX-101 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT06159725 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.